Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Vertex names chief medical officer Reshma Kewalramani as new CEO

by Lisa M. Jarvis
August 2, 2019 | A version of this story appeared in Volume 97, Issue 31
Advertisement

Most Popular in Pharmaceuticals

 

A headshot of incoming Vertex CEO Reshma Kewalramani.
Credit: Vertex Pharmaceuticals
Reshma Kewalramani

Next year will bring a changing of the guard at Vertex Pharmaceuticals. In April 2020, Jeffrey Leiden will step down as CEO and become executive chairman of the board of directors. Leiden became CEO in 2012 and led the Boston-based biotech company through the launch and expansion of its lucrative cystic fibrosis drug franchise. Chief Medical Officer Reshma Kewalramani, who joined Vertex in 2017 after more than 12 years at the biotech firm Amgen, will become the next CEO. Kewalramani will be the first woman to lead a top-five biotech firm.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society

You might also like...

Mikael Dolsten, Pfizer’s top scientist, to step down
Serving the chemical, life science, and laboratory worlds
Merck KGaA appoints Belén Garijo its CEO
Serving the chemical, life science, and laboratory worlds
Biotech firm Agios picks Fouse as CEO

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE